

(b) - contacting the respective amplificates with a probe each time having a binding sequence D which can bind to the sequence B located between the sequences A and C or to the complement thereof, and

(c) - detecting the formation of a hybrid of the amplificate and a probe.

wherein the sequence located between the binding sequences A and C contains no nucleotides or less than 3 nucleotides that do not belong to the sequence section E formed from the binding sequence D of the probe and the sequence of the amplificate bound thereto and the amplificates are shorter than 100 nucleotides.

25. (Amended) The method of [Method as claimed in] claim 24, wherein amplificates of nucleic acids of HIV, HBV and HCV are produced simultaneously.

REMARKS

Applicants have amended the claims to comply with U.S. patent practice in matters of form and to remove certain multiple dependency. After entry of this Amendment, claims 1-25 are pending in this application. The amendments do not introduce new matter. Entry of this Amendment is respectfully requested.

The total filing fee on the Transmittal Letter To The United States Designated/Elected Office (DO/EO/US) Concerning A Filing Under 35 U.S.C. §371 is calculated on the basis of this Amendment.

Respectfully submitted

By: 

Victor K. Lee, Ph.D.
Agent for Applicants
Reg. No. 35,750
Roche Molecular Systems, Inc.
1145 Atlantic Avenue
Alameda, CA 94501
Telephone (510) 814-2966
Telefax (510) 814-2973